Patent application number | Description | Published |
20090118311 | DHFR Enzyme Inhibitors - Compounds of formula (I) or (II) are dihydrofolate reductase inhibitors, useful for the treatment of, for example, cell proliferative diseases: | 05-07-2009 |
20090291978 | Enzyme Inhibitors - Compounds of formula (I) are inhibitors of histone deacetylase activity, and are useful in the treatment of, for example, cancers, wherein R | 11-26-2009 |
20090298924 | HYDROXAMIC ACID DERIVATIVES AS INHIBITORS OF HDAC ENZYMATIC ACTIVITY - Compounds of formula (I) are inhibitors of histone deacetylase activity, and are useful in the treatment of, for example, cancers: | 12-03-2009 |
20100010010 | HDAC INHIBITORS - Compounds of formula (I) inhibit HDAC activity, wherein A, B and D independently represent ═C— or ═N—; W is a divalent radical —CH═CH— or CH | 01-14-2010 |
20100317678 | HYDROXAMATES AS INHIBITORS OF HISTONE DEACETYLASE - Compounds of formula (I), and salts, N-oxides, hydrates and solvates thereof are histone deacetylase inhibitors and are useful in the treatment of cell proliferative diseases, including cancers: | 12-16-2010 |
20100317865 | ENZYME AND RECEPTOR MODULATION - Covalent conjugates of an α,α-disubstituted glycine ester and a modulator of the activity of a target intracellular enzyme or receptor, wherein the ester group of the conjugate is hydrolysable by one or more intracellular carboxylesterase enzymes to the corresponding acid and the α,α-disubstituted glycine ester is conjugated to the modulator at a position remote from the binding interface between the inhibitor and the target enzyme or receptor pass into cells and the active acid hydrolysis product accumulates within the cells. | 12-16-2010 |
20130197042 | HDAC INHIBITORS - Compounds of formula (I) inhibit HDAC activity: | 08-01-2013 |
Patent application number | Description | Published |
20090131461 | Quinoline and quinoxaline derivatives as inhibitors of kinase enzymatic activity - Compounds of formula (IA) or (IB), are inhibitors of aurora kinase activity: Formula (IA), (IB) wherein -L1Y1-[CH2]z- is a linker radical wherein Y | 05-21-2009 |
20090215800 | Enzyme and Receptor Modulation - Covalent conjugation of an alpha amino acid ester to a modulator of the activity of a target intracellular enzyme or receptor, wherein the ester group of the conjugate is hydrolysable by one or more intracellular carboxylesterase enzymes to the corresponding acid, leads to accumulation of the carboxylic acid hydrolysis product in the cell and enables improved or more prolonged enzyme or receptor modulation relative to the unconjugated modulator. | 08-27-2009 |
20130116318 | Enzyme Inhibitors - Compounds of formula (I) are inhibitors of histone deacetylase activity, and are useful in the treatment of, for example, cancers: | 05-09-2013 |
20140088159 | ENZYME AND RECEPTOR MODULATION - Covalent conjugates of an α,α-disubstituted glycine ester and a modulator of the activity of a target intracellular enzyme or receptor, wherein the ester group of the conjugate is hydrolysable by one or more intracellular carboxylesterase enzymes to the corresponding acid and the α,α-disubstituted glycine ester is conjugated to the modulator at a position remote from the binding interface between the inhibitor and the target enzyme or receptor pass into cells and the active acid hydrolysis product accumulates within the cells. | 03-27-2014 |
20140163042 | ENZYME INHIBITORS - Compounds of formula (I) are inhibitors of histone deacetylase activity, and are useful in the treatment of, for example, cancers, wherein R | 06-12-2014 |
20140323531 | HDAC INHIBITORS - Compounds of formula (I) inhibit HDAC activity: | 10-30-2014 |